EL7.AI
StocksMediumUpdated•Originally published 21 July 2026•Updated 22 July 2026•
2 min read

PolyPid Secures $320M Commercialization Deal with Azurity for D-PLEX₁₀₀

Key Facts

1PolyPid entered an exclusive partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX₁₀₀ in the U.S. and Canada.
2The agreement includes potential payments exceeding $320 million, with $30 million upfront and in the near term.
3Roth Capital reaffirmed a 'Buy' rating for PolyPid following successful Phase 3 clinical trial results.

In a strategic move to bolster its commercial presence in the pharmaceutical market, PolyPid has entered into an exclusive partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX₁₀₀ in the U.S. and Canada. According to reports, the agreement involves potential milestone payments exceeding $320 million, with $30 million structured as upfront and near-term payments. The partnership aims to leverage Azurity's established commercial infrastructure for a planned market launch in the first quarter of 2027.

The deal coincides with PolyPid reporting strong financial results for the first quarter of 2026, strengthening the company's balance sheet for its clinical operations. Consequently, H.C. Wainwright has reiterated its 'Buy' rating for PolyPid with a specific price target of $13, while Roth Capital also maintains a positive stance. Per market data, this valuation reflects significant upside potential following the successful Phase 3 clinical trial results and the recent FDA application submission.

PYPD shares stood at $3.74 at close July 20, 2026, leaving substantial room for growth toward the newly reaffirmed price targets. Investors are now watching for further regulatory milestones and the execution of the non-dilutive funding streams provided by the Azurity partnership. On the broader economic front, traders are looking ahead to the U.S. Producer Price Index (PPI) data on July 15, which may influence risk sentiment across the biotech sector.